Biomimetic Design of Artificial Hybrid Nanocells for Boosted Vascular Regeneration in Ischemic Tissues

Zhang, Xiangyun; Zhang, Yue; Zhang, Ran; Jiang, Xinbang; Midgley, Adam C.; Liu, Qiqi; Kang, Helong; Wu, Jin; Khalique, Anila; Qian, Meng; An, Di; Huang, Jing; Ou, Lailiang; Zhao, Qiang; Zhuang, Jie; Yan, Xiyun

doi:10.1002/adma.202110352

Cited by 41 publications

(41 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cell‐membrane‐coated PLGA nanoparticles were prepared as previously described. [ 21 ] Briefly, the cell membrane (containing 12.5 µg of protein) was added into 1 mL of PLGA nanoparticles (4 mg mL −1 ), followed by sonication for 5 min using a water bath sonicator. Then, the mixture was extruded 20 times through a 400 nm polycarbonate porous membrane with an Avanti mini extruder to prepare the cell‐membrane‐coated PLGA nanoparticles (i.e., Nano‐AAM).…”

Section: Methodsmentioning

confidence: 99%

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane

Zhang

Wang

et al. 2023

Advanced Materials

Self Cite

View full text Add to dashboard Cite

training the immune system. [1] Whole tumor cell vaccines are capable of providing a wide range of various autologous antigens; thus, they have been considered a promising strategy to overcome the ineffectiveness of single-antigen vaccination. [2] However, whole tumor cell vaccines have shown less impressive clinical outcomes, as compared to the current clinical efficacy of adoptive T-cell therapy and immune checkpoint blockade. [3] This probably results from the significant presence of a large amount of housekeeping genes, nucleic acids, and lipids, which dilute the antitumor efficacy of the whole cell vaccines. [2c,d,4] To address this challenge, the purified tumor cell membrane and/ or cell lysate have been broadly utilized as the source of antigens to develop the biomimetic cancer nanovaccines in recent years. [5] In addition to the selection of the best antigenic materials, a more important challenge of tumor-cell-based vaccines is the lack of costimulatory signals to activate immune cells. [3b,6] Thus, developing the appropriate approach to endow costimulatory signals has been considered as the primary choice to improve the clinical efficacy of tumor vaccine therapy. Contrary to the inhibitory immune checkpoints (e.g., programmed cell death protein-1/programmed death-ligand1 (PD1/ PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)) that attenuate the immune responses, the costimulatory Despite the promise in whole-tumor cell vaccines, a key challenge is to overcome the lack of costimulatory signals. Here, agonistic-antibody-boosted tumor cell nanovaccines are reported by genetically engineered antibodyanchored membrane (AAM) technology, capable of effectively activating costimulatory pathways. Specifically, the AAM can be stably constructed following genetic engineering of tumor cell membranes with anti-CD40 single chain variable fragment (scFv), an agonistic antibody to induce costimulatory signals. The nanovaccines are versatilely designed and obtained based on the anti-CD40 scFv-anchored membrane and nanotechnology. Following vaccination, the anti-CD40 scFv-anchored membrane nanovaccine (Nano-AAM/ CD40) significantly facilitates dendritic cell maturation in CD40-humanized transgenic mice and subsequent adaptive immune responses. Compared to membrane-based nanovaccines alone, the enhanced antitumor efficacy in both "hot" and "cold" tumor models of the Nano-AAM/CD40 demonstrates the importance of agonistic antibodies in development of tumor-cell-based vaccines. To expand the design of nanovaccines, further incorporation of cell lysates into the Nano-AAM/CD40 to conceptually construct tumor cell-like nanovaccines results in boosted immune responses and improved antitumor efficacy against malignant tumors inoculated into CD40-humanized transgenic mice. Overall, this genetically engineered AAM technology provides a versatile design of nanovaccines by incorporation of tumor-cell-based components and agonistic antibodies of costimulatory immune checkpoints.

show abstract

Section: Methodsmentioning

confidence: 99%

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane

Zhang

Wang

et al. 2023

Advanced Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, a microparticle system by integration the secreted factors from 3D cell spheroids with cell membrane-derived coating was developed and showed superior revascularization effects in hindlimb ischemia model 27 . Most recently, instead of loading growth factors to promote angiogenesis, we constructed a novel delivery system with surface coating of copper-containing protein to timely release nitric oxide (NO) 141 . A rational designed nanovesicle was achieved by collection both of membrane and secretome from MSCs cultured in the presence of inflammatory cytokines via a one-step extrusion strategy 142 .…”

Section: Treatment Of Ischemic Diseases Using Nanomedicinesmentioning

confidence: 99%

Targeted delivery of nanomedicines for promoting vascular regeneration in ischemic diseases

Zhuang¹,

Zhang²,

Liu³

et al. 2022

Theranostics

Self Cite

View full text Add to dashboard Cite

Ischemic diseases, the leading cause of disability and death, are caused by the restriction or blockage of blood flow in specific tissues, including ischemic cardiac, ischemic cerebrovascular and ischemic peripheral vascular diseases. The regeneration of functional vasculature network in ischemic tissues is essential for treatment of ischemic diseases. Direct delivery of pro-angiogenesis factors, such as VEGF, has demonstrated the effectiveness in ischemic disease therapy but suffering from several obstacles, such as low delivery efficacy in disease sites and uncontrolled modulation. In this review, we summarize the molecular mechanisms of inducing vascular regeneration, providing the guidance for designing the desired nanomedicines. We also introduce the delivery of various nanomedicines to ischemic tissues by passive or active targeting manner. To achieve the efficient delivery of nanomedicines in various ischemic diseases, we highlight targeted delivery of nanomedicines and controllable modulation of disease microenvironment using nanomedicines.

show abstract

“…Currently, nanoparticles drugs in cardiovascular disease have gradually changed from traditional small molecules particle delivery to proteins, nucleic acids, and other biological macromolecules ( Bejerano, Etzion, Elyagon, Etzion, and Cohen, 2018 ; Hong et al, 2020 ; Kwon et al, 2021 ; S. Liu et al, 2020 ; Mihalko et al, 2018 ; Wang Q et al, 2021 ; X. Zhang et al, 2022 ). Taking the delivery of miRs as an example, miR-1, 133, 208, and 499 are capable of cardiac reprogramming, and the conversion of fibroblasts into induced cardiomyocyte-like cells is expected to be a new approach for the treatment of myocardial fibrosis.…”

Section: Biomaterials In Myocardial Fibrosis Studies and Therapymentioning

confidence: 99%

Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy

Xiong

Zheng³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Myocardial fibrosis is the result of abnormal healing after acute and chronic myocardial damage and is a direct cause of heart failure and cardiac insufficiency. The clinical approach is to preserve cardiac function and inhibit fibrosis through surgery aimed at dredging blood vessels. However, this strategy does not adequately address the deterioration of fibrosis and cardiac function recovery. Therefore, numerous biomaterial platforms have been developed to address the above issues. In this review, we summarize the existing biomaterial delivery and restoring platforms, In addition, we also clarify the therapeutic strategies based on biomaterial platforms, including general strategies to block the fibrosis process and new strategies to promote cellular restoring effects. The development of structures with the ability to block further fibrosis progression as well as to promote cardiomyocytes viability should be the main research interests in myocardial fibrosis, and the reestablishment of structures necessary for normal cardiac function is central to the treatment of myocardial fibrosis. Finally, the future application of biomaterials for myocardial fibrosis is also highlighted.

show abstract

Biomimetic Design of Artificial Hybrid Nanocells for Boosted Vascular Regeneration in Ischemic Tissues

Cited by 41 publications

References 39 publications

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane

Tumor Cell Nanovaccines Based on Genetically Engineered Antibody‐Anchored Membrane

Targeted delivery of nanomedicines for promoting vascular regeneration in ischemic diseases

Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy

Contact Info

Product

Resources

About